参松养心胶囊治疗病毒性心肌炎的Meta分析

Meta-analysis of Shensongyangxin Capsules treating viral myocarditis

目的系统评价参松养心胶囊治疗病毒性心肌炎的效果和安全性,为参松养心胶囊治疗病毒性心肌炎提供相关的循证医学依据。方法计算机检索PubMed、EMbase、Cochrane Library、CBM、WanFang、CNKI和VIP数据库建库至2016年11月4日的CCT和RCT,并对全部纳入文献的参考文献进行追溯,由两位评价者根据纳入排除标准独立对文献进行筛选和评价,然后进行数据提取。运用RevMan 5.3软件进行统计分析。结果共纳入12篇文献,Meta分析显示,参松养心组对病毒性心肌炎的临床综合疗效优于西药组(OR值为3.19,95%可信区间为2.14~4.74,P<0.01);参松养心组对病毒性心肌炎室性心律失常的疗效优于西药组(OR值为3.64,95%可信区间为2.50~5.30,P<0.01);参松养心组的不良反应事件发生率低且较轻微。结论参松养心胶囊治疗病毒性心肌炎的效果显著,安全性较好。

Objective To review systematically the effect and safety of Shensongyangxin Capsules treating viral myocarditis,and provide the related basis of evidence based medicine for Shensongyangxin Capsules treating viral my- ocarditis.Methods PubMed,EMbase,Cochrane Library,CBM,WanFang,CNKI and VIP were retrieved using the computer for collecting RCT and CCT for database construction to November 4,2016,and all references included in the literature were traced.According to the inclusion and exclusion criteria,two reviewers screened and assessed independently the literature,and then the data was extracted.The data was given a Meta-analysis by using RevMan 5.3 software.Results 12 study articles were included.Meta-analysis showed that the clinical curative effect of the Shensongyangxin group treating viral myocarditis was better than the Western medicine group （OR=3.19,95%CI：2.14-4.74,P〈O.01）.The clinical curative effect of the Shensongyangxin group treating ventricular arrhythmia was better than the Western medicine group （OR=3.64,95%CI：2.50-5.30,P〈0.01）.The occurrence rate of adverse events was lower and the reactions was low and mild in the Shensongyangxin group.Conclusion Shensongyangxin Capsules has a significant curative effect treating viral myocarditis,and the safety is good.